Please find below a video abstract summarising the study design of a randomised, placebo-controlled trial of nintedanib in children and adolescents with fibrosing interstitial lung disease: InPedILD™

 

Citation: Robin Deterding, Matthias Griese, Gail Deutsch, David Warburton, Emily M. DeBoer, Steven Cunningham, Annick Clement, Nicolaus Schwerk, Kevin R. Flaherty, Kevin K. Brown, Florian Voss, Ulrike Schmid, Rozsa Schlenker-Herceg, Daniela Verri, Mihaela Dumistracel, Marilisa Schiwek, Susanne Stowasser, Kay Tetzlaff, Emmanuelle Clerisme-Beaty, Lisa R. Young. Study design of a randomised, placebo-controlled trial of nintedanib in children and adolescents with fibrosing interstitial lung disease. ERJ Open Res 2021; 7: 00805-2020.

DOI: 10.1183/23120541.00805-2020.

ClinicalTrials.gov: NCT04093024

Header - Navigation Icon

The InPedILD™ trial was supported by Boehringer Ingelheim International GmbH (BI). The authors meet criteria for authorship as recommended by the International Committee of Medical Journal Editors (ICMJE). The authors did not receive payment for the development of the video abstract. Writing support was provided by Islay Steele, PhD, of Nucleus Global, and was contracted and funded by BI.BI was given the opportunity to review the poster for medical and scientific accuracy as well as intellectual property considerations.